Posts by Sandra Ansanay-Alex
Oculis Secures FDA Backing and Full Ownership of Privosegtor
Oculis Holding AG, a Zug-based biopharmaceutical company with operations in Lausanne, has had a decisive first two weeks of August 2026, combining positive US regulatory feedback with a strategic acquisition that together strengthen its position in neuro-ophthalmology. Positive FDA pre-IND feedback for acute MS relapses On August 3, Oculis announced that the FDA’s Division of…
Read MoreTimeline Wins $5.3 Million Court Judgment Against Fake Urolithin A Sellers
Timeline (Amazentis SA), the Lausanne-Based life-sciences company behind the postbiotic ingredient Urolithin A and its branded form Mitopure®, has secured a major legal victory in the United States. On July 15, 2026, the U.S. District Court for the District of Massachusetts permanently banned 19 online sellers from marketing or selling fraudulent Urolithin A products and…
Read MoreHAYA Therapeutics granted Fast Track designation by the FDA for HTX-001
HAYA Therapeutics SA, a clinical-stage biotechnology company based in Lausanne and San Diego, announced that the US Food and Drug Administration (FDA) has granted Fast Track designation to HTX-001, its therapeutic candidate for symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM). HTX-001 is an antisense oligonucleotide designed to reduce the expression of *WISPER*, a cardiac stress-specific long non-coding…
Read MoreAB2 Bio Secures $30 Million as Nippon Shinyaku Exercises US Commercialization Rights for Tadekinig Alfa
AB2 Bio, a Swiss Health Valley and EPFL based company, has announced that Nippon Shinyaku has exercised its exclusive option to commercialize Tadekinig alfa in the United States, following positive exchanges with the FDA. Under the agreement, AB2 Bio will receive an upfront payment of $30 million and is eligible for up to $600 million…
Read MoreHeroSupport Starts Clinical Study With NYU Grossman School of Medicine
HeroSupport SA is a UNIGE and HUG spin out and created VENUS SHELL™ , a 3D-printed support that enables accurate, reproducible, and more comfortable positioning during radiation therapy for breast cancer patients. HeroSupport SA is advancing patient immobilisation in prone breast cancer radiotherapy. The CE-marked VENUS SHELL™ is a patient-specific, 3D-printed support that enables accurate,…
Read MoreImpli and Molesense Selected for Germany’s SPRIND Continuous Hormone Monitoring Challenge
MoleSense and Impli, two startups based at Biopôle near Lausanne, have both been selected by Germany’s Federal Agency for Breakthrough Innovation (SPRIND) for its Continuous Hormone Monitoring Challenge — a three-year programme backing biosensor technologies capable of tracking at least four hormones continuously over seven days, with up to €1.5 million in Stage 1 funding…
Read MorePlanimetrics Receives CHF 40,000 from Venture Kick
Planimetrics, formerly Laxiped, is a life-sciences project, spun out University of Geneva (UNIGE) and Assal Center, working on a solution to support foot and ankle surgeons diagnostics and decicion-making. First ray instability is a foot condition still diagnosed mainly through physical examination — a gap Planimetrics is working to close. The company has been awarded…
Read MoreThree Wins for the Swiss Health Valley: Recognition for Unboound, DIVERSSITY and Prof. Nicolas Winssinger
From clinical innovation to fundamental science, each of these Swiss Health Valley entrepreneurs and researchers were recognised at the highest level their respective field : ORL, AI-Driven Mental Health therapy and and Medicinal Chemistry. Dr. Julien Wen Hsieh wins the Grand Prix 2026 of the Swiss Society of ORL Dr. Julien Wen Hsieh, CEO and…
Read MoreMasimo Wins its Legal Battle Against Apple and is Set to Receive a Cheque for $634 million
Masimo, which has been headquartered in Neuchâtel since 2008 and employs over 100 staff there at the heart of the Swiss Health Valley, has just won one of the most closely watched legal cases in the technology industry. The US courts have definitively dismissed Apple’s appeal, confirming that the Californian firm must pay $634 million…
Read MoreGivaudan and Nestlé: a Challenging First Semester for the two Swiss Health Valley Powerhouses
Two of Switzerland’s biggest names in industry unveiled their half-year results on Thursday, and the stock market did not respond well. Givaudan and Nestlé, both based in the Lake Geneva region, saw their share prices fall sharply at the opening bell, driven by disappointing figures despite some encouraging signs. At Givaudan, the flavour and fragrance…
Read More